With 0.14 million shares changed hands, the volume of the stock remained heavier than its average volume of 53720.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $39.065 whereas the lowest price it dropped to was $37.0. The 52-week range on LYEL shows that it touched its highest point at $45.00 and its lowest point at $7.65 during that stretch. It currently has a 1-year price target of $29.67. Beta for the stock currently stands at -0.12.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LYEL was up-trending over the past week, with a rise of 20.36%, but this was up by 69.89% over a month. Three-month performance surged to 203.46% while six-month performance rose 323.25%. The stock gained 201.56% in the past year, while it has gained 215.00% so far this year. A look at the trailing 12-month EPS for LYEL yields -22.95 with Next year EPS estimates of -9.05. For the next quarter, that number is -2.37. This implies an EPS growth rate of 59.56% for this year and 14.66% for next year. EPS is expected to grow by 31.67% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -19.90%.
Float and Shares Shorts:
At present, 19.29 million LYEL shares are outstanding with a float of 6.94 million shares on hand for trading. On 2025-11-28, short shares totaled 0.16 million, which was 76.0 higher than short shares on 1761868800. In addition to Dr. Richard D. Klausner M.D. as the firm’s Founder & Executive Chairman, Dr. Lynn Seely M.D., Ph.D. serves as its Interim Principal Financial Officer, Principal Executive Officer, President, CEO & Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, LYEL reported revenue of $15000.0 and operating income of -$37253000.0. The EBITDA in the recently reported quarter was -$34687000.0 and diluted EPS was -$2.13.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for LYEL since 3 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With LYEL analysts setting a high price target of 45.0 and a low target of 12.0, the average target price over the next 12 months is 29.66667. Based on these targets, LYEL could surge 16.58% to reach the target high and fall by -68.91% to reach the target low. Reaching the average price target will result in a decline of -23.14% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$14.41282 being high and -$14.6 being low. For LYEL, this leads to a yearly average estimate of -$14.6. The surprise factor in the prior quarter was -$3.58. Based on analyst estimates, the high estimate for the next quarter is -$2.12 and the low estimate is -$2.16. The average estimate for the next quarter is thus -$2.14.
